Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in Moderate-to-Severe Prurigo Nodularis
NCT06773403Phase 4Terminated
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
- Start
- Apr 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of upadacitinib in prurigo nodularis (PN), sponsored by Psoriasis Treatment Center of Central New Jersey. Started Apr 2024; status: terminated.
02
Drugs
upadacitinib
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on NCT06773403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06773403.